Among patients with cardiovascular disease and high lipoprotein(a) levels, pelacarsen lowered the lipoprotein(a) level, but the risk of major cardiovascular events was similar with pelacarsen and placebo. Full phase 3 Lp(a)HORIZON trial results: https://nej.md/4AcZL9n
#ScientificSessions26
#ScientificSessions26
November 7, 2026 at 2:55 PM
Among patients with cardiovascular disease and high lipoprotein(a) levels, pelacarsen lowered the lipoprotein(a) level, but the risk of major cardiovascular events was similar with pelacarsen and placebo. Full phase 3 Lp(a)HORIZON trial results: https://nej.md/4AcZL9n
#ScientificSessions26
#ScientificSessions26
Outer membrane lipoprotein sensing for T6SS retaliation
Outer membrane lipoprotein sensing for T6SS retaliation
The type VI secretion system (T6SS) is an antimicrobial weapon that Gram-negative bacteria use to outcompete other microbes within polymicrobial communities. Recently, Kolesnikov et al. reported that Pseudomonas aeruginosa can use the T6SS in a precise and responsive manner by sensing T6SS attack via the outer membrane lipoprotein TagQ.
dlvr.it
November 5, 2026 at 8:23 PM
Outer membrane lipoprotein sensing for T6SS retaliation
Physicians were excited about several therapies that slash levels of lipoprotein(a), an important cardiovascular risk factor. A feature in Nature outlines how one major clinical trial failed to show a benefit and how scientists are scrambling to work out what that means. #medsky 🧪
This cholesterol drug promised to be a game-changer. Why did it flop in the clinic — and is there still hope?
Physicians were excited about several therapies that slash levels of lipoprotein(a) — an important cardiovascular risk factor. One major trial failed to show a benefit, and now scientists are scrambling to work out what that means.
go.nature.com
November 8, 2026 at 5:28 PM
Physicians were excited about several therapies that slash levels of lipoprotein(a), an important cardiovascular risk factor. A feature in Nature outlines how one major clinical trial failed to show a benefit and how scientists are scrambling to work out what that means. #medsky 🧪
Highly anticipated cholesterol drug fails to prevent heart attacks, strokes
The drug, Novartis’ pelacarsen, should have worked against lipoprotein(a), a genetic type of cholesterol that causes plaque to build up in arteries, researchers said. Why didn’t it?
www.nbcnews.com/health/healt...
The drug, Novartis’ pelacarsen, should have worked against lipoprotein(a), a genetic type of cholesterol that causes plaque to build up in arteries, researchers said. Why didn’t it?
www.nbcnews.com/health/healt...
The ‘slam dunk’ that wasn’t: Promising cholesterol drug fails to prevent heart attacks or stroke
The drug, Novartis’ pelacarsen, should have worked against lipoprotein(a), a genetic type of cholesterol that causes plaque to build up in arteries, researchers said. Why didn’t it?
www.nbcnews.com
November 9, 2026 at 2:31 AM
Highly anticipated cholesterol drug fails to prevent heart attacks, strokes
The drug, Novartis’ pelacarsen, should have worked against lipoprotein(a), a genetic type of cholesterol that causes plaque to build up in arteries, researchers said. Why didn’t it?
www.nbcnews.com/health/healt...
The drug, Novartis’ pelacarsen, should have worked against lipoprotein(a), a genetic type of cholesterol that causes plaque to build up in arteries, researchers said. Why didn’t it?
www.nbcnews.com/health/healt...
Researchers report triglyceride/high-density lipoprotein cholesterol ratio - a surrogate marker of insulin resistance, "may provide prognostic information & help identify early-stage #Parkinsons patients at risk of worse disease progression"
www.prd-journal.com/article/S135...
www.prd-journal.com/article/S135...
November 8, 2026 at 1:23 PM
Researchers report triglyceride/high-density lipoprotein cholesterol ratio - a surrogate marker of insulin resistance, "may provide prognostic information & help identify early-stage #Parkinsons patients at risk of worse disease progression"
www.prd-journal.com/article/S135...
www.prd-journal.com/article/S135...
Doctors were excited about this cholesterol drug - why did it flop in the clinic?
go.nature.com/4elVKqD
go.nature.com/4elVKqD
This cholesterol drug promised to be a game-changer. Why did it flop in the clinic — and is there still hope?
Nature - Physicians were excited about several therapies that slash levels of lipoprotein(a) — an important cardiovascular risk factor. One major trial failed to show a benefit, and now scientists...
go.nature.com
November 7, 2026 at 3:20 PM
Doctors were excited about this cholesterol drug - why did it flop in the clinic?
go.nature.com/4elVKqD
go.nature.com/4elVKqD
Jede:r Fünfte hat hohe Werte: Pelacarsen senkte Risikofaktor #Lipoprotein(a), schützte in NEJM-Studie aber überraschend nicht vor z.B. Herzinfarkt. Expert:innen diskutierten Gründe, Implikationen für Betroffene und Erwartungen an weitere Forschung: sciencemediacenter.de/angebote/ris...
November 9, 2026 at 9:15 AM
Jede:r Fünfte hat hohe Werte: Pelacarsen senkte Risikofaktor #Lipoprotein(a), schützte in NEJM-Studie aber überraschend nicht vor z.B. Herzinfarkt. Expert:innen diskutierten Gründe, Implikationen für Betroffene und Erwartungen an weitere Forschung: sciencemediacenter.de/angebote/ris...
Ist damit Lipoprotein gemeint?
November 6, 2026 at 4:07 AM
Ist damit Lipoprotein gemeint?
Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a) | New England Journal of Medicine www.nejm.org/doi/full/10....
Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a) | NEJM
Pelacarsen, an antisense oligonucleotide, reduces serum levels of lipoprotein(a).
However, the effect of pelacarsen on cardiovascular outcomes remains uncertain. We
conducted an international, rand...
www.nejm.org
November 9, 2026 at 2:23 PM
Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a) | New England Journal of Medicine www.nejm.org/doi/full/10....
Ist ein erhöhter Lipoprotein-a-Wert doch nicht so aussagekräftig?
Ist ein erhöhter Lipoprotein-a-Wert doch nicht so aussagekräftig?
Er gilt als wichtiger Faktor in Sachen Herz-Kreislauf-Risiko: der Lipoprotein-a-Wert. Doch lang erwartete Studienergebnisse fallen nun überraschend negativ aus.
dlvr.it
November 7, 2026 at 3:04 PM
Ist ein erhöhter Lipoprotein-a-Wert doch nicht so aussagekräftig?
The failure of the Novartis drug pelacarsen to help people who have high levels of lipoprotein(a) stunned researchers, who called it a massive blow to preventive cardiology. on.nbcboston.com/UzjbvQB
The ‘slam dunk’ that wasn’t: Promising cholesterol drug fails to prevent heart attacks or stroke
The drug, Novartis’ pelacarsen, should have worked against lipoprotein(a), a genetic type of cholesterol that causes plaque to build up in arteries, researchers said. Why didn’t it?
on.nbcboston.com
November 8, 2026 at 1:08 AM
The failure of the Novartis drug pelacarsen to help people who have high levels of lipoprotein(a) stunned researchers, who called it a massive blow to preventive cardiology. on.nbcboston.com/UzjbvQB
Pelacarsen lowered lipoprotein(a) levels by about 78% but failed to prevent cardiovascular complications in high-risk adults over five years.
Save What Matters
Curate Feeds | Make Collections | Customize Email Briefs
briefly.co
November 7, 2026 at 3:13 PM
Pelacarsen lowered lipoprotein(a) levels by about 78% but failed to prevent cardiovascular complications in high-risk adults over five years.
For many, lipoprotein(a) was the "missing link" in cardiovascular risk. However, after years of searching for a treatment, the first clinical trial has failed—a result that has come as a shock.
This is an account of what is currently known, ahead of the full results being unveiled this Saturday.
This is an account of what is currently known, ahead of the full results being unveiled this Saturday.
Lipoprotein (a): what we know about the new hope for cardiovascular health and its publicised failure
Lipoprotein (a) is a particle that is very similar to, but distinct from, LDL, the ‘bad cholesterol’. Regarded as the hidden factor in cardiovascular risk, some scientific societies recommend that it ...
sciencemediacentre.es
November 6, 2026 at 8:47 AM
For many, lipoprotein(a) was the "missing link" in cardiovascular risk. However, after years of searching for a treatment, the first clinical trial has failed—a result that has come as a shock.
This is an account of what is currently known, ahead of the full results being unveiled this Saturday.
This is an account of what is currently known, ahead of the full results being unveiled this Saturday.
“Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).”
Publié ce jour dans le @nejm.org et présenté au congrès de #AHA.
#Medsky
www.nejm.org/doi/full/10....
Publié ce jour dans le @nejm.org et présenté au congrès de #AHA.
#Medsky
www.nejm.org/doi/full/10....
Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a) | NEJM
Pelacarsen, an antisense oligonucleotide, reduces serum levels of lipoprotein(a). However, the effect of pelacarsen on cardiovascular outcomes remains uncertain. We conducted an international, rand...
www.nejm.org
November 7, 2026 at 3:05 PM
“Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).”
Publié ce jour dans le @nejm.org et présenté au congrès de #AHA.
#Medsky
www.nejm.org/doi/full/10....
Publié ce jour dans le @nejm.org et présenté au congrès de #AHA.
#Medsky
www.nejm.org/doi/full/10....
Pelacarsen targets a stealthy and particularly lethal form of cholesterol called lipoprotein(a), or Lp(a). Much like low-density lipoprotein — LDL, or the “bad” cholesterol — Lp(a) causes plaque to build up in arteries. But it also helps form blood clots, and unlike LDL, it is entirely genetic.
November 9, 2026 at 2:33 AM
Pelacarsen targets a stealthy and particularly lethal form of cholesterol called lipoprotein(a), or Lp(a). Much like low-density lipoprotein — LDL, or the “bad” cholesterol — Lp(a) causes plaque to build up in arteries. But it also helps form blood clots, and unlike LDL, it is entirely genetic.
Experts were left flabbergasted, shocked. The lipoprotein(a) studies that leave us in the lurch. garyschwitzer.substack.com/p/what-we-ca...
November 9, 2026 at 1:07 PM
Experts were left flabbergasted, shocked. The lipoprotein(a) studies that leave us in the lurch. garyschwitzer.substack.com/p/what-we-ca...
A promising drug for an inherited heart risk flops, stunning doctors
A promising drug for an inherited heart risk flops, stunning doctors | CNN
Results are in for a highly anticipated study of an experimental drug meant to reduce major heart events by lowering lipoprotein (a). To the surprise of doctors, the drug didn’t work.
www.cnn.com
November 8, 2026 at 3:24 PM
A promising drug for an inherited heart risk flops, stunning doctors
I can see how this would be so disappointing to researchers, but it's a very interesting null result.
A drug that successfully reduced lipoprotein(a) [Lp(a)] levels by 78% did not translate into any reduced risk of heart attack or stroke.
A drug that successfully reduced lipoprotein(a) [Lp(a)] levels by 78% did not translate into any reduced risk of heart attack or stroke.
November 7, 2026 at 5:58 PM
I can see how this would be so disappointing to researchers, but it's a very interesting null result.
A drug that successfully reduced lipoprotein(a) [Lp(a)] levels by 78% did not translate into any reduced risk of heart attack or stroke.
A drug that successfully reduced lipoprotein(a) [Lp(a)] levels by 78% did not translate into any reduced risk of heart attack or stroke.
Lower lipoprotein(a), better outcomes? Why the distinction matters
Science on Caterpillars
Science on Caterpillars
Lower lipoprotein(a), better outcomes? Why the distinction matters
A risk marker can fall without a trial demonstrating clinical benefit. Nature’s news feature describes therapies that sharply lower lipoprotein(a), an important cardiovascular risk factor, but reports that one major trial failed to show a benefit. That distinction is worth keeping front and centre:…
caterpilla.rs
November 6, 2026 at 1:33 PM
Lower lipoprotein(a), better outcomes? Why the distinction matters
Science on Caterpillars
Science on Caterpillars
Hear from Viet Le, DMSc, PA-C, FACC, FAHA, HF- Cert! 🎥
Lp(a) HORIZON, presented at #ScientificSessions26 showed Pelacarsen substantially lowered lipoprotein(a) but did not reduce risk of MACE compared to placebo in patients on guideline-directed medical therapy for secondary prevention of CVD.
Lp(a) HORIZON, presented at #ScientificSessions26 showed Pelacarsen substantially lowered lipoprotein(a) but did not reduce risk of MACE compared to placebo in patients on guideline-directed medical therapy for secondary prevention of CVD.
November 7, 2026 at 9:02 PM
Hear from Viet Le, DMSc, PA-C, FACC, FAHA, HF- Cert! 🎥
Lp(a) HORIZON, presented at #ScientificSessions26 showed Pelacarsen substantially lowered lipoprotein(a) but did not reduce risk of MACE compared to placebo in patients on guideline-directed medical therapy for secondary prevention of CVD.
Lp(a) HORIZON, presented at #ScientificSessions26 showed Pelacarsen substantially lowered lipoprotein(a) but did not reduce risk of MACE compared to placebo in patients on guideline-directed medical therapy for secondary prevention of CVD.
Analysis of reproductive traits associated with lipoprotein(a) deficiency in participants from the Pakistan Genome Resource https://www.biorxiv.org/content/10.64898/2026.11.05.764746v1
November 7, 2026 at 12:30 AM
Analysis of reproductive traits associated with lipoprotein(a) deficiency in participants from the Pakistan Genome Resource https://www.biorxiv.org/content/10.64898/2026.11.05.764746v1
Experimental Heart Drug Shows No Benefit in Major Trial
Background: The promise of a new heart medication For years researchers have chased a drug that could reduce low density lipoprotein, a well known ri
https://bloggersminds.com/post/experimental-heart-drug-shows-no-benefit-in-major-trial-10335
Background: The promise of a new heart medication For years researchers have chased a drug that could reduce low density lipoprotein, a well known ri
https://bloggersminds.com/post/experimental-heart-drug-shows-no-benefit-in-major-trial-10335
Experimental Heart Drug Shows No Benefit in Major Trial
Background: The promise of a new heart medication For years researchers have chased a drug that could reduce low density lipoprotein, a well known risk factor for heart attacks. The experimental compound, developed by a biotech firm, appeared to lower this marker in early laboratory work and small scale studies.
bloggersminds.com
November 7, 2026 at 4:00 PM
Experimental Heart Drug Shows No Benefit in Major Trial
Background: The promise of a new heart medication For years researchers have chased a drug that could reduce low density lipoprotein, a well known ri
https://bloggersminds.com/post/experimental-heart-drug-shows-no-benefit-in-major-trial-10335
Background: The promise of a new heart medication For years researchers have chased a drug that could reduce low density lipoprotein, a well known ri
https://bloggersminds.com/post/experimental-heart-drug-shows-no-benefit-in-major-trial-10335
Elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for cardiovascular disease, making early identification and intervention important for long-term heart health.
November 8, 2026 at 4:03 PM
Elevated low-density lipoprotein cholesterol (LDL-C) is a major risk factor for cardiovascular disease, making early identification and intervention important for long-term heart health.